Laseroptek Co. Ltd. Announces U.S. Launch of Pallas Solid-state UVB Medical Dermatology Laser

August 12, 2020

Laseroptek Co. Ltd., a developer and manufacturer of laser devices for aesthetic and medical dermatology, has announced the launch of its Pallas solid-state 311-nm UVB laser in the United States. The Pallas laser is FDA-cleared for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma.
Pallas is the fifth Laseroptek laser device to receive FDA clearance in the U.S. for dermatological treatments and brings to the U.S. market the world’s first solid-state UVB laser delivering efficacious and safe treatment for a variety of skin conditions that collectively affect close to a billion people worldwide.
Read more at PR Newswire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • PracticeQ Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Fresh Clinics Acquires Spakinect
    • Arkansas Nursing Board Comment Deadline Approaching for Medical Aesthetics and IV Hydration Guidance
    • Acquisition Lets AI and Operators Learn From Nearly $2 Billion in Annual Aesthetics Transactions
    • Longevity, Safety, and Innovation: Merz Aesthetics on Natural Results and the Future of Regenerative Aesthetics